Business Model

Sinclair Pharma enters the healthcare product cycle after the initial high-risk research phase. The company focuses on acquiring innovative products that are late in the development cycle, have intellectual property (IP) protection, or can be IP protected. Sinclair targets products that are undervalued, and applies regulatory expertise to gain registration for these products so that their commercial potential can be unlocked.

The products are then commercialised in two ways:

	Sinclair has built up a network of reputable marketing partners that spans 82 countries. Strong sales growth has been seen through working closely with these companies, and this network is still expanding.
	We are also focused on achieving additional growth by developing our own sales and marketing organisations in selected major territories. This will allow Sinclair to have greater control over its brands, and to achieve higher margins. These organisations are now established in France, the UK, Italy, Spain and Portgual.

Operations

Sinclair Pharma now has approximately 150 employees.  A breakdown of our presence is shown here on page 3 of our Annual Report.

These operations include ther corporate headquarters in Godalming, England, and sales and marketing operations in France, the UK, Italy Spain and Portugal.

Marketing Partners

Sinclair has a network of reputable marketing partners in 82 countries. For more information please click here.